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The Hellenic Society of Gastroenterology [1] recently 
published the National consensus on Helicobacter pylori 
(H. pylori) infection, following the necessity of a uniform 
approach to yield optimal eradication rates. As implied by 
the recent Maastricht V/Florence consensus [2], an “add-on” 
strategy regarding antibiotics was adapted to overleap the 
increasing antibiotic resistance, combined with the absence 
of bismuth-containing drugs, thus perpetuating a “vicious 
circle” and emerging novel approaches in treatment models 
with a targeted pathophysiological perspective. Importantly, 
parameters connected with the multidrug resistance include 
the formation of H. pylori-related biofilms, suggesting the 
introduction of novel anti-biofilm therapeutic approaches 
using anti-biofilm agents [3].
A unanimous suggestion (Statement 10) proposed that H. 
pylori culture or molecular techniques should be conducted 
to evaluate the antimicrobial susceptibility. Nevertheless, 
those methods are characterized by limited availability in 
most regions. On the other hand, recent data imply a potential 
benefit of vitamin D (vitD) for H. pylori infection treatment, 
related to the vitD-receptor’s (VDR) antimicrobial role [4-6]. 
VDR, stimulated by the active H. pylori infection, induces 
human β-defensins, which in high concentrations suppress 
H. pylori biofilm activity [3]; subtle or strong activation of 
VDR, due to vitD absence or adequacy, could contribute 
or not to H. pylori acclimatization, morbidity, resistance, 
and survival [3]. Additionally, vitD seems to act directly 
as an antibacterial agent through stimulation of defensins 
and cathelicidins, and vitD upregulated protein 1 (VDP1). 
possesses an H. pylori-specific antimicrobial ability, indicating 
a promising therapeutic potential [7,8]. Moreover, studies in 
mouse models revealed a protective role of a VDP1 against 
H. pylori-related gastric cancer [9]. Clinical studies concluded 
that vitD had a protective role against H. pylori infection and 
suggested its deficiency as a distinct risk factor in the failure of 
eradication treatment, while a recent meta-analysis concluded 
that vitD supplementation could change the effectiveness of 
eradication regimens [10]. Therefore, a National multicenter 
study has recently been inaugurated to elucidate the 
relationship between vitD and H. pylori infection and the 
potential beneficial effect of vitD supplementation during 
eradication treatment.
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We read with great interest the letter by Papaefthymiou 
et al [1] concerning the Greek National Consensus on 
Helicobacter pylori (H. pylori) infection [2]. We certainly agree 
with the authors that over the past years in order to overcome 
the fast-growing antibiotic resistance of H. pylori infection 
worldwide, an “add-on” strategy has been adapted, and that 
this is more obvious in countries like Greece, where bismuth 
salts are not commercially available. Thus, novel H. pylori 
eradication regimens, with a more targeted pathophysiological 
approach, are under evaluation and we are awaiting with great 
interest the results of the ongoing clinical trials.
Eradication of H. pylori infection has traditionally relied on 
empiric therapeutic regimens, since the need for endoscopy 
and the limited availability of culture, in most countries 
including Greece, have rendered the susceptibility-guided 
treatment option impractical or even unfeasible. Moreover, a 
recent randomized study showed that susceptibility-guided 
therapy in a high-resistance area was equally effective as a local 
empirical regimen [3], while another randomized study failed 
to reveal superiority of genotypic resistance-guided therapy 
over a properly designed empirical treatment for eradication 
of refractory H. pylori infection [4]. For these reasons, the 
Greek consensus has stated (Statement 26) that culture and 
antimicrobial susceptibility testing is not recommended before 
first-line therapy, and that susceptibility-guided therapy should 
be provided as a rescue treatment, especially after second-line 
treatment has failed.
On the other hand, the effect of vitamin D (vitD) on 
H. pylori infection and eradication rates has been widely 
investigated recently [5]. VitD, apart from its well-known role 
in calcium and phosphorus metabolism, has been proven to 
be potent immune modulator of the adaptive immune system, 
stimulating the innate immune response upon infection [6]. 
Based on these data, several clinical studies have illustrated 
that vitD analogs may have anti-H. pylori antimicrobial effects. 
Cytological research has also found that vitD
3
 decomposition 
product 1 can lyse  H. pylori  bacterial cells by inducing the 
collapse of the cell membrane [7]. However, the correlation 
with vitD has not been fully clarified and studies of the impact 
of serum vitD levels on H. pylori eradication were mostly 
observational or retrospective and of small sample size [8-10]. 
Therefore, well-designed randomized controlled prospective 
studies with a large sample size are needed. We were delighted 
to hear that a national multicenter study on the relationship 
between vitD and H. pylori was recently launched and we are 
awaiting the results.
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